Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

Donald L. Lamm, Brent A. Blumenstein, E. David Crawford, John D. Crissman, Bruce A. Lowe, Joseph A. Smith, Michael F. Sarosdy, Paul F. Schellhammer, Arthur I. Sagalowsky, Edward M. Messing, Patrick Loehrer, H. Barton Grossman

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

To compare the toxicity and efficacy of intravesical bacillus Calmette-Guérin (BCG) immunotherapy and mitomycin C (MMC) chemotherapy in the prophylaxis of recurrent transitional cell carcinoma, 469 patients with completely resected stage Ta or TI transitional cell carcinoma were enrolled in a randomized Southwest Oncology Group Phase III study. All patients were judged to be at increased risk for tumor recurrence due to having had two occurrences of tumor within 56 weeks, stage T I tumor or three or more tumors within 16 weeks, or concurrent carcinoma in situ. Three hundred and seventy-seven evaluable patients received either 50 mg of Tice BCG in 50 cc saline or 20 mg MMC in 20 cc water weekly for 6 weeks and then monthly to one year. Local and systemic grade I and 2 toxicity was seen significantly more frequently following BCG treatment (P = 0.003), but no life threatening toxicity was seen with either treatment. Recurrence-free survival was significantly prolonged (P = 0.017, proportional hazard regression) in patients randomized to the BCG arm compared to the MMC arm, but there were no statistically significant differences at this analysis for worsening-free survival and overall survival, although the number of these events is too low for a definitive analysis of these long-term outcomes. Therefore, when compared to MMC chemotherapy, BCG immunotherapy is associated with a significantly higher frequency of grade 1 and 2 adverse reactions and a significantly lower first recurrence hazard rate.

Original languageEnglish
Pages (from-to)119-126
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume1
Issue number3
DOIs
StatePublished - 1995

Fingerprint

Transitional Cell Carcinoma
Mitomycin
Mycobacterium bovis
Immunotherapy
Bacillus
Urinary Bladder
Drug Therapy
Recurrence
Survival
Neoplasms
Carcinoma in Situ
Water
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. / Lamm, Donald L.; Blumenstein, Brent A.; David Crawford, E.; Crissman, John D.; Lowe, Bruce A.; Smith, Joseph A.; Sarosdy, Michael F.; Schellhammer, Paul F.; Sagalowsky, Arthur I.; Messing, Edward M.; Loehrer, Patrick; Barton Grossman, H.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 1, No. 3, 1995, p. 119-126.

Research output: Contribution to journalArticle

Lamm, Donald L. ; Blumenstein, Brent A. ; David Crawford, E. ; Crissman, John D. ; Lowe, Bruce A. ; Smith, Joseph A. ; Sarosdy, Michael F. ; Schellhammer, Paul F. ; Sagalowsky, Arthur I. ; Messing, Edward M. ; Loehrer, Patrick ; Barton Grossman, H. / Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. In: Urologic Oncology: Seminars and Original Investigations. 1995 ; Vol. 1, No. 3. pp. 119-126.
@article{93703c5dfcd64750b7249b1c6b760b3e,
title = "Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study",
abstract = "To compare the toxicity and efficacy of intravesical bacillus Calmette-Gu{\'e}rin (BCG) immunotherapy and mitomycin C (MMC) chemotherapy in the prophylaxis of recurrent transitional cell carcinoma, 469 patients with completely resected stage Ta or TI transitional cell carcinoma were enrolled in a randomized Southwest Oncology Group Phase III study. All patients were judged to be at increased risk for tumor recurrence due to having had two occurrences of tumor within 56 weeks, stage T I tumor or three or more tumors within 16 weeks, or concurrent carcinoma in situ. Three hundred and seventy-seven evaluable patients received either 50 mg of Tice BCG in 50 cc saline or 20 mg MMC in 20 cc water weekly for 6 weeks and then monthly to one year. Local and systemic grade I and 2 toxicity was seen significantly more frequently following BCG treatment (P = 0.003), but no life threatening toxicity was seen with either treatment. Recurrence-free survival was significantly prolonged (P = 0.017, proportional hazard regression) in patients randomized to the BCG arm compared to the MMC arm, but there were no statistically significant differences at this analysis for worsening-free survival and overall survival, although the number of these events is too low for a definitive analysis of these long-term outcomes. Therefore, when compared to MMC chemotherapy, BCG immunotherapy is associated with a significantly higher frequency of grade 1 and 2 adverse reactions and a significantly lower first recurrence hazard rate.",
author = "Lamm, {Donald L.} and Blumenstein, {Brent A.} and {David Crawford}, E. and Crissman, {John D.} and Lowe, {Bruce A.} and Smith, {Joseph A.} and Sarosdy, {Michael F.} and Schellhammer, {Paul F.} and Sagalowsky, {Arthur I.} and Messing, {Edward M.} and Patrick Loehrer and {Barton Grossman}, H.",
year = "1995",
doi = "10.1016/1078-1439(95)00041-F",
language = "English",
volume = "1",
pages = "119--126",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

AU - Lamm, Donald L.

AU - Blumenstein, Brent A.

AU - David Crawford, E.

AU - Crissman, John D.

AU - Lowe, Bruce A.

AU - Smith, Joseph A.

AU - Sarosdy, Michael F.

AU - Schellhammer, Paul F.

AU - Sagalowsky, Arthur I.

AU - Messing, Edward M.

AU - Loehrer, Patrick

AU - Barton Grossman, H.

PY - 1995

Y1 - 1995

N2 - To compare the toxicity and efficacy of intravesical bacillus Calmette-Guérin (BCG) immunotherapy and mitomycin C (MMC) chemotherapy in the prophylaxis of recurrent transitional cell carcinoma, 469 patients with completely resected stage Ta or TI transitional cell carcinoma were enrolled in a randomized Southwest Oncology Group Phase III study. All patients were judged to be at increased risk for tumor recurrence due to having had two occurrences of tumor within 56 weeks, stage T I tumor or three or more tumors within 16 weeks, or concurrent carcinoma in situ. Three hundred and seventy-seven evaluable patients received either 50 mg of Tice BCG in 50 cc saline or 20 mg MMC in 20 cc water weekly for 6 weeks and then monthly to one year. Local and systemic grade I and 2 toxicity was seen significantly more frequently following BCG treatment (P = 0.003), but no life threatening toxicity was seen with either treatment. Recurrence-free survival was significantly prolonged (P = 0.017, proportional hazard regression) in patients randomized to the BCG arm compared to the MMC arm, but there were no statistically significant differences at this analysis for worsening-free survival and overall survival, although the number of these events is too low for a definitive analysis of these long-term outcomes. Therefore, when compared to MMC chemotherapy, BCG immunotherapy is associated with a significantly higher frequency of grade 1 and 2 adverse reactions and a significantly lower first recurrence hazard rate.

AB - To compare the toxicity and efficacy of intravesical bacillus Calmette-Guérin (BCG) immunotherapy and mitomycin C (MMC) chemotherapy in the prophylaxis of recurrent transitional cell carcinoma, 469 patients with completely resected stage Ta or TI transitional cell carcinoma were enrolled in a randomized Southwest Oncology Group Phase III study. All patients were judged to be at increased risk for tumor recurrence due to having had two occurrences of tumor within 56 weeks, stage T I tumor or three or more tumors within 16 weeks, or concurrent carcinoma in situ. Three hundred and seventy-seven evaluable patients received either 50 mg of Tice BCG in 50 cc saline or 20 mg MMC in 20 cc water weekly for 6 weeks and then monthly to one year. Local and systemic grade I and 2 toxicity was seen significantly more frequently following BCG treatment (P = 0.003), but no life threatening toxicity was seen with either treatment. Recurrence-free survival was significantly prolonged (P = 0.017, proportional hazard regression) in patients randomized to the BCG arm compared to the MMC arm, but there were no statistically significant differences at this analysis for worsening-free survival and overall survival, although the number of these events is too low for a definitive analysis of these long-term outcomes. Therefore, when compared to MMC chemotherapy, BCG immunotherapy is associated with a significantly higher frequency of grade 1 and 2 adverse reactions and a significantly lower first recurrence hazard rate.

UR - http://www.scopus.com/inward/record.url?scp=58149363358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149363358&partnerID=8YFLogxK

U2 - 10.1016/1078-1439(95)00041-F

DO - 10.1016/1078-1439(95)00041-F

M3 - Article

VL - 1

SP - 119

EP - 126

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -